GalectoGLTO
About: Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Employees: 13
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
4.61% less ownership
Funds ownership: 14.9% [Q2] → 10.29% (-4.61%) [Q3]
18% less capital invested
Capital invested by funds: $1.92M [Q2] → $1.56M (-$353K) [Q3]
59% less funds holding
Funds holding: 22 [Q2] → 9 (-13) [Q3]
87% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 15
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 7
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Oppenheimer Jay Olson 27% 1-year accuracy 14 / 52 met price target | 66%upside $10 | Outperform Maintained | 17 Oct 2024 |
